Edward B Silberstein1. 1. Departments of Radiology and Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio edward.silberstein@uchealth.com.
Abstract
UNLABELLED: We studied the changing patterns of radiopharmaceutical use and the incidence of adverse events (AEs) to PET radiopharmaceuticals, non-PET radiopharmaceuticals, and adjunctive nonradioactive pharmaceuticals in nuclear medicine from 2007 to 2011. METHODS: Fifteen academic institutions submitted quarterly reports of radiopharmaceutical use and AEs covering 2007-2011. RESULTS: 1,024,177 radiopharmaceutical administrations were monitored: 207,281 diagnostic PET, 803,696 diagnostic non-PET, and 13,200 therapeutic. In addition, 112,830 adjunctive nonradioactive pharmaceutical administrations were monitored. The annual use of bone scintigraphy and radiotracer therapies was unchanged. PET radiopharmaceutical use increased from 17% to 26% of diagnostic procedures (P < 0.01). The incidence of radiopharmaceutical AEs was 2.1/10(5) administrations, with no hospitalizations or deaths. CONCLUSION: From 2007 to 2011, PET studies increased, and therapeutic radiopharmaceutical use and bone scintigraphy were unchanged. Over 2 decades, the incidence of AEs has remained stable at 2.1-2.3/10(5) dosages.
UNLABELLED: We studied the changing patterns of radiopharmaceutical use and the incidence of adverse events (AEs) to PET radiopharmaceuticals, non-PET radiopharmaceuticals, and adjunctive nonradioactive pharmaceuticals in nuclear medicine from 2007 to 2011. METHODS: Fifteen academic institutions submitted quarterly reports of radiopharmaceutical use and AEs covering 2007-2011. RESULTS: 1,024,177 radiopharmaceutical administrations were monitored: 207,281 diagnostic PET, 803,696 diagnostic non-PET, and 13,200 therapeutic. In addition, 112,830 adjunctive nonradioactive pharmaceutical administrations were monitored. The annual use of bone scintigraphy and radiotracer therapies was unchanged. PET radiopharmaceutical use increased from 17% to 26% of diagnostic procedures (P < 0.01). The incidence of radiopharmaceutical AEs was 2.1/10(5) administrations, with no hospitalizations or deaths. CONCLUSION: From 2007 to 2011, PET studies increased, and therapeutic radiopharmaceutical use and bone scintigraphy were unchanged. Over 2 decades, the incidence of AEs has remained stable at 2.1-2.3/10(5) dosages.
Authors: Shannon M Bates; Anita Rajasekhar; Saskia Middeldorp; Claire McLintock; Marc A Rodger; Andra H James; Sara R Vazquez; Ian A Greer; John J Riva; Meha Bhatt; Nicole Schwab; Danielle Barrett; Andrea LaHaye; Bram Rochwerg Journal: Blood Adv Date: 2018-11-27
Authors: Sue Bunning; Christopher Ignace; Steve Mattmuller; Sally W Schwarz; Peter J H Scott; Henry F VanBrocklin; Steven S Zigler Journal: J Nucl Med Date: 2022-01-20 Impact factor: 11.082
Authors: Michael K O'Connor; Melissa M B Morrow; Katie N Hunt; Judy C Boughey; Dietlind L Wahner-Roedler; Amy Lynn Conners; Deborah J Rhodes; Carrie B Hruska Journal: EJNMMI Res Date: 2017-01-14 Impact factor: 3.138
Authors: Carl von Gall; Piotr Maniawski; Fred Verzijlbergen; Ignasi Carrio; Thomas Beyer; Antonis Kalemis Journal: Eur J Nucl Med Mol Imaging Date: 2017-08-14 Impact factor: 9.236
Authors: Nanno Schreuder; Quincy de Hoog; Sieta T de Vries; Pieter L Jager; Jos G W Kosterink; Eugène P van Puijenbroek Journal: Drug Saf Date: 2020-04 Impact factor: 5.606